Leonel Ochoa

1.3k total citations
23 papers, 873 citations indexed

About

Leonel Ochoa is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Leonel Ochoa has authored 23 papers receiving a total of 873 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 10 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Leonel Ochoa's work include Multiple Myeloma Research and Treatments (7 papers), Cancer Treatment and Pharmacology (5 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Leonel Ochoa is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Cancer Treatment and Pharmacology (5 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Leonel Ochoa collaborates with scholars based in United States, Mexico and France. Leonel Ochoa's co-authors include Eric K. Rowinsky, Anthony W. Tolcher, Amita Patnaik, Louis Denis, Johann S. de Bono, Bahram Forouzesh, Andrew Goetz, Jorge Olmos, Alain C. Mita and Muralidhar Beeram and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Leonel Ochoa

23 papers receiving 841 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leonel Ochoa United States	11	313	263	232	213	200	23	873
Maroof Alam United States	24	559 1.8×	1.2k 4.5×	239 1.0×	83 0.4×	174 0.9×	26	1.6k
Huajing Wang China	20	317 1.0×	693 2.6×	117 0.5×	53 0.2×	105 0.5×	61	1.5k
S. Danhauser-Riedl Germany	15	347 1.1×	392 1.5×	61 0.3×	422 2.0×	57 0.3×	34	1.1k
Christian Viskov France	17	110 0.4×	417 1.6×	19 0.1×	125 0.6×	93 0.5×	27	854
Alexios J. Aletras Greece	18	216 0.7×	427 1.6×	101 0.4×	20 0.1×	56 0.3×	35	1.0k
Hiroyuki Shiokawa Japan	14	214 0.7×	298 1.1×	50 0.2×	41 0.2×	51 0.3×	64	775
Ioannis Kagiampakis United States	14	151 0.5×	621 2.4×	61 0.3×	54 0.3×	56 0.3×	25	1000
L Robson United Kingdom	13	486 1.6×	503 1.9×	84 0.4×	27 0.1×	26 0.1×	22	889
Maureen E. Lane United States	15	368 1.2×	307 1.2×	167 0.7×	40 0.2×	46 0.2×	26	816
Christian Gerecke Germany	19	318 1.0×	578 2.2×	45 0.2×	309 1.5×	30 0.1×	26	1.2k

Countries citing papers authored by Leonel Ochoa

Since Specialization

Citations

This map shows the geographic impact of Leonel Ochoa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonel Ochoa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonel Ochoa more than expected).

Fields of papers citing papers by Leonel Ochoa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonel Ochoa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonel Ochoa. The network helps show where Leonel Ochoa may publish in the future.

Co-authorship network of co-authors of Leonel Ochoa

This figure shows the co-authorship network connecting the top 25 collaborators of Leonel Ochoa. A scholar is included among the top collaborators of Leonel Ochoa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonel Ochoa. Leonel Ochoa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Junmin, Joseph A. Pidala, Taiga Nishihori, et al.. (2020). Delayed CD4+ T-Cell but Faster B-Cell Immune Reconstitution after Ptcy-Based Compared to Conventional Gvhd Prophylaxis after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation. 26(3). S308–S309. 2 indexed citations

Grajales‐Cruz, Ariel, Kenneth H. Shain, Jason Brayer, et al.. (2019). Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis. Blood. 134(Supplement_1). 3183–3183. 4 indexed citations

Ochoa, Leonel, et al.. (2014). Complex Carbohydrates as a Possible Source of High Energy to Formulate Functional Feeds. Advances in food and nutrition research. 73. 259–288. 7 indexed citations

López, Lus M., et al.. (2014). Evaluation of carbohydrate-to-lipid ratio in diets supplemented withBacillus subtilisprobiotic strain on growth performance, body composition and digestibility in juvenile white seabass (Atractoscion nobilis,Ayres 1860). Aquaculture Research. 47(6). 1864–1873. 14 indexed citations

Olmos-Soto, Jorge, et al.. (2012). DNA Fingerprinting Intron-Sizing Method to Accomplish a Specific, Rapid, and Sensitive Identification of Carotenogenic Dunaliella Species. Methods in molecular biology. 892. 269–281. 3 indexed citations

Baz, Rachid, Kenneth H. Shain, Melissa Alsina, et al.. (2012). Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort. Blood. 120(21). 4062–4062. 8 indexed citations

Alsina, Melissa, Rachid Baz, Kenneth H. Shain, et al.. (2012). Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease. Blood. 120(21). 4071–4071. 3 indexed citations

Baz, Rachid, Melissa Alsina, Kenneth H. Shain, et al.. (2012). Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults with Newly Diagnosed Standard Risk Multiple Myeloma. Blood. 120(21). 4060–4060. 2 indexed citations

Santarone, Stella, Joseph Pidala, Marta Di Nicola, et al.. (2011). Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia. Biology of Blood and Marrow Transplantation. 17(10). 1505–1511. 23 indexed citations

10.

Pidala, Joseph, Jongphil Kim, Heather Jim, et al.. (2011). Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd. Blood. 118(21). 323–323. 1 indexed citations

11.

Shain, Kenneth H., Daniel M. Sullivan, Melissa Alsina, et al.. (2011). Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,. Blood. 118(21). 3979–3979. 1 indexed citations

12.

Olmos, Jorge, et al.. (2011). Functional Feed Assessment on Litopenaeus vannamei Using 100% Fish Meal Replacement by Soybean Meal, High Levels of Complex Carbohydrates and Bacillus Probiotic Strains. Marine Drugs. 9(6). 1119–1132. 76 indexed citations

13.

Nishihori, Taiga, Leonel Ochoa, Joseph Pidala, et al.. (2011). A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma,. Blood. 118(21). 4158–4158. 3 indexed citations

14.

Shain, Kenneth H., Melissa Alsina, Leonel Ochoa, et al.. (2011). Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma. Blood. 118(21). 5142–5142. 1 indexed citations

15.

Perkins, Janelle, Teresa Field, Jongphil Kim, et al.. (2010). A Randomized Phase II Trial Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate for Acute Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation. 16(7). 937–947. 89 indexed citations

16.

Olmos, Jorge, et al.. (2009). DNA fingerprinting differentiation between β-carotene hyperproducer strains of Dunaliella from around the world. PubMed. 5(1). 5–5. 24 indexed citations

17.

Raza, Azra, Naomi Galili, Natalie S. Callander, et al.. (2009). Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. Journal of Hematology & Oncology. 2(1). 20–20. 49 indexed citations

18.

Mita, Alain C., Louis Denis, Eric K. Rowinsky, et al.. (2009). Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(2). 723–730. 260 indexed citations

19.

Tolcher, Anthony W., Leonel Ochoa, Lisa A. Hammond, et al.. (2003). Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. Journal of Clinical Oncology. 21(2). 211–222. 146 indexed citations

20.

Rowinsky, Eric K., Jinee Rizzo, Leonel Ochoa, et al.. (2002). A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology. 21(1). 148–157. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact